Pharmacoinvasive Strategy for STEMI When Primary PCI Is Delayed

Immediate Diagnosis & Initial Therapy

Obtain and interpret a 12‑lead ECG within 10 minutes of first medical contact to confirm STEMI and define “time zero.” (ESC guideline) 1
Give aspirin 150–325 mg orally (or 250–500 mg IV if unable to swallow) immediately at first contact. (ESC guideline, Class I, Level A) 2
If primary PCI cannot be achieved within 120 minutes, initiate fibrinolytic therapy within 10 minutes of diagnosis, preferably in the pre‑hospital setting. (ESC guideline, Class I, Level A) 3

Use a fibrin‑specific thrombolytic agent; tenecteplase is preferred for single‑bolus administration, with alteplase or reteplase as alternatives. (ESC guideline) 1
Administer a clopidogrel loading dose of 300–600 mg immediately; clopidogrel is the only P2Y12 inhibitor recommended with fibrinolysis, and prasugrel or ticagrelor should not be used initially. (ESC guideline, Class I, Level A) 2
Prefer enoxaparin given as an IV bolus followed by sub‑cutaneous dosing; unfractionated heparin (weight‑adjusted IV bolus then infusion) is acceptable if enoxaparin is unavailable. (ESC guideline) 1
Continue anticoagulation (enoxaparin or UFH) until definitive revascularisation or for the duration of the hospital stay, up to a maximum of 8 days. (ESC guideline) 2

Transfer all patients to a PCI‑capable centre immediately after fibrinolysis; do not wait to assess reperfusion success. (ESC guideline, Class I, Level A) 3
Notify the receiving PCI centre during ambulance transport so the catheter‑lab can be prepared. (ESC guideline) 2
Perform emergency (immediate) angiography for patients with heart failure or cardiogenic shock, hemodynamic/electrical instability, failed fibrinolysis (≤ 50 % ST‑segment resolution at 60–90 min), or recurrent ischemia/re‑occlusion. (ESC guideline) 1
For hemodynamically stable patients with successful reperfusion (≥ 50 % ST‑segment resolution), schedule routine angiography 2–24 hours after fibrinolysis and do not delay beyond 24 hours. (ESC guideline, Class I, Level A) 3

At the time of angiography/PCI, switch from clopidogrel to prasugrel (60 mg loading) or ticagrelor (180 mg loading). (ESC guideline) 2
Continue dual antiplatelet therapy (aspirin + prasugrel or ticagrelor) for 12 months unless contraindicated by high bleeding risk. (ESC guideline, Class I, Level A) 1
If the patient has not been anticoagulated or received enoxaparin > 8 hours earlier, give unfractionated heparin during PCI. (ESC guideline) 2

Do not use prasugrel or ticagrelor as the initial P2Y12 inhibitor with fibrinolysis; clopidogrel is required. (ESC guideline) 1
Do not delay transfer to assess reperfusion; all patients need angiography regardless of clinical response. (ESC guideline) 2
Do not miss the 2–24 hour window for routine angiography after successful fibrinolysis; adherence improves outcomes. (ESC guideline, reinforced by ACC/AHA) 3
Do not attempt primary PCI if the expected door‑to‑balloon time exceeds 120 minutes; fibrinolysis followed by transfer yields better outcomes. (ACC/AHA guideline) 3
Do not use fondaparinux as anticoagulation in this pathway; it is contraindicated for primary PCI. (ESC guideline) 2

In low‑ and middle‑income countries, the pharmacoinvasive pathway is the most feasible and desirable STEMI strategy when primary PCI cannot be delivered within 120 minutes. (ACC/AHA guideline) 3
Pre‑hospital fibrinolysis administered by EMS further shortens time to reperfusion and should be adopted wherever logistics allow. (ACC/AHA guideline) 3
Regional STEMI networks that connect non‑PCI hospitals to PCI centres via coordinated EMS improve patient outcomes. (ACC/AHA guideline) 4
Delivering reperfusion within the “golden hour” (first 60–90 minutes after symptom onset) can halve mortality; fibrinolysis often achieves this faster than primary PCI in real‑world scenarios. (ACC/AHA guideline) 3

The European Society of Cardiology recommends initiating fibrinolytic therapy immediately when primary PCI cannot be performed within 120 minutes of STEMI diagnosis, using a fibrin-specific agent (tenecteplase, alteplase, or reteplase) preferably in the pre-hospital setting, combined with aspirin, clopidogrel, and enoxaparin anticoagulation 5
Administer fibrinolytic therapy when primary PCI is not available within 120 minutes of STEMI diagnosis in patients presenting within 12 hours of symptom onset with persistent ST-segment elevation and no contraindications (Class I, Level A) 5
The benefit of fibrinolytic therapy is greatest within the first 3 hours of symptom onset, with every minute of delay increasing myocardial necrosis 6

Use a fibrin-specific thrombolytic agent: tenecteplase, alteplase, or reteplase (Class I, Level B) 5
Administer oral or IV aspirin (if unable to swallow) as soon as possible (Class I, Level B) 5
Give clopidogrel immediately in addition to aspirin when fibrinolysis is the reperfusion strategy (Class I, Level A) 5, 7
Enoxaparin is preferred: IV bolus followed by subcutaneous administration (preferred over unfractionated heparin, Class I, Level A) 5, 7

Transfer all patients to a PCI-capable center immediately after fibrinolysis (Class I, Level A) 5, 7
Perform routine angiography between 2-24 hours after successful fibrinolysis (Class I, Level A) 5, 7
Switch from clopidogrel to prasugrel or ticagrelor at the time of PCI, and maintain for 12 months unless contraindications exist (Class I, Level A) 6, 7

Perform routine echocardiography during hospital stay to assess LV/RV function, detect mechanical complications, and exclude LV thrombus 5

Do not use prasugrel or ticagrelor as the initial P2Y12 inhibitor with fibrinolytic therapy—clopidogrel is specifically indicated in this setting 7
Do not delay transfer to a PCI-capable center—all patients require angiography regardless of apparent lysis success 7
Do not miss the 2-24 hour window for routine angiography after successful fibrinolysis 7
Do not use fondaparinux for primary PCI (Class III, Level B) 5